Details of the Drug Combinations

General Information of This Drug (ID: DM3WDZ5)

Drug Name
MK-1775   DM3WDZ5
Synonyms
MK-1775; 955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219
Indication
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

676 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
(-)-englerin A + MK-1775 DC3ADN9 (-)-englerin A Ewing sarcoma (Cell Line: TC-71) [3]
ABT-263 + MK-1775 DCN0QN8 ABT-263 Ewing sarcoma (Cell Line: TC-71) [4]
AXL-1717 + MK-1775 DCO6YJ1 AXL-1717 Ewing sarcoma (Cell Line: TC-71) [3]
Cyclophosphamide + MK-1775 DCN4OAO Cyclophosphamide Adenocarcinoma (Cell Line: OVCAR3) [3]
Cyclophosphamide + MK-1775 DCNEQCX Cyclophosphamide Adenocarcinoma (Cell Line: NCIH1650) [3]
Cyclophosphamide + MK-1775 DCT3617 Cyclophosphamide Adenocarcinoma (Cell Line: NCIH2122) [3]
Cyclophosphamide + MK-1775 DCM5RPR Cyclophosphamide Adenocarcinoma (Cell Line: HT29) [3]
Cyclophosphamide + MK-1775 DCESAQK Cyclophosphamide Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Cyclophosphamide + MK-1775 DC9XN22 Cyclophosphamide Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
Decitabine + MK-1775 DCR8YIC Decitabine Ewing sarcoma (Cell Line: TC-71) [3]
Dexamethasone + MK-1775 DC7JABQ Dexamethasone Adenocarcinoma (Cell Line: OVCAR3) [4]
Dexamethasone + MK-1775 DCWR38P Dexamethasone Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Doxorubicin + MK-1775 DCUP72V Doxorubicin Adenocarcinoma (Cell Line: CAOV3) [3]
Doxorubicin + MK-1775 DCHIOXR Doxorubicin Hodgkin lymphoma (Cell Line: U-HO1) [3]
Doxorubicin + MK-1775 DC762VA Doxorubicin Malignant melanoma (Cell Line: RPMI7951) [3]
Doxorubicin + MK-1775 DCNRCTP Doxorubicin Mesothelioma (Cell Line: MSTO) [3]
Doxorubicin + MK-1775 DCGKX71 Doxorubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Epothilone D + MK-1775 DC3XDB0 Epothilone D Ewing sarcoma (Cell Line: TC-71) [3]
Estramustine + MK-1775 DCXBAE9 Estramustine Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Estramustine + MK-1775 DC8RIYX Estramustine Breast and ovarian cancer syndrome (Cell Line: UWB1289) [5]
Estramustine + MK-1775 DC05PAU Estramustine Breast carcinoma (Cell Line: OCUBM) [5]
Estramustine + MK-1775 DCL04CS Estramustine Carcinoma (Cell Line: EFM192B) [5]
Estramustine + MK-1775 DCFP73J Estramustine Colon adenocarcinoma (Cell Line: LOVO) [5]
Estramustine + MK-1775 DCCGIN3 Estramustine Invasive ductal carcinoma (Cell Line: T-47D) [5]
Estramustine + MK-1775 DC32TT3 Estramustine Adenocarcinoma (Cell Line: CAOV3) [4]
Estramustine + MK-1775 DCYRSFL Estramustine Adenocarcinoma (Cell Line: A427) [4]
Estramustine + MK-1775 DCMW6FP Estramustine Adenocarcinoma (Cell Line: NCIH2122) [4]
Estramustine + MK-1775 DC5Q9HY Estramustine Adenocarcinoma (Cell Line: NCIH520) [4]
Estramustine + MK-1775 DCSF1LK Estramustine Adenocarcinoma (Cell Line: COLO320DM) [4]
Estramustine + MK-1775 DC61LSG Estramustine Adenocarcinoma (Cell Line: DLD1) [4]
Estramustine + MK-1775 DCA5QO6 Estramustine Adenocarcinoma (Cell Line: HT29) [4]
Estramustine + MK-1775 DCIZKVL Estramustine Adenocarcinoma (Cell Line: SW-620) [4]
Estramustine + MK-1775 DCASYQW Estramustine Amelanotic melanoma (Cell Line: A2058) [4]
Estramustine + MK-1775 DCS0RVF Estramustine Germ cell tumour (Cell Line: PA1) [4]
Estramustine + MK-1775 DCLJNJ2 Estramustine Malignant melanoma (Cell Line: A375) [4]
Estramustine + MK-1775 DCO8IQQ Estramustine Malignant melanoma (Cell Line: HT144) [4]
Estramustine + MK-1775 DCS0WS5 Estramustine Malignant melanoma (Cell Line: RPMI7951) [4]
Estramustine + MK-1775 DCE6FX0 Estramustine Malignant melanoma (Cell Line: SKMEL30) [4]
Estramustine + MK-1775 DC9SD03 Estramustine Mesothelioma (Cell Line: MSTO) [4]
Estramustine + MK-1775 DC8484L Estramustine Non small cell carcinoma (Cell Line: SKMES1) [4]
Estramustine + MK-1775 DCJBZYW Estramustine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Etoposide + MK-1775 DCFB4LH Etoposide Adenocarcinoma (Cell Line: CAOV3) [3]
Etoposide + MK-1775 DC3GGQD Etoposide Adenocarcinoma (Cell Line: NCIH2122) [3]
Etoposide + MK-1775 DC12MK4 Etoposide Adenocarcinoma (Cell Line: NCIH520) [3]
Etoposide + MK-1775 DCG7OO3 Etoposide Adenocarcinoma (Cell Line: COLO320DM) [3]
Etoposide + MK-1775 DCN9QZH Etoposide Adenocarcinoma (Cell Line: HCT116) [3]
Etoposide + MK-1775 DCDT878 Etoposide Adenocarcinoma (Cell Line: HT29) [3]
Etoposide + MK-1775 DC35IR0 Etoposide Amelanotic melanoma (Cell Line: A2058) [3]
Etoposide + MK-1775 DC4TR78 Etoposide Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Etoposide + MK-1775 DCV6OVC Etoposide Malignant melanoma (Cell Line: A375) [3]
Etoposide + MK-1775 DCKLQP1 Etoposide Malignant melanoma (Cell Line: RPMI7951) [3]
Etoposide + MK-1775 DCW9MLK Etoposide Malignant melanoma (Cell Line: SKMEL30) [3]
Etoposide + MK-1775 DC0RP68 Etoposide Mesothelioma (Cell Line: MSTO) [3]
Etoposide + MK-1775 DCT7T04 Etoposide Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Etoposide + MK-1775 DCUDZX1 Etoposide Prostate carcinoma (Cell Line: VCAP) [3]
Etoposide + MK-1775 DCTEUUY Etoposide Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
Etoposide + MK-1775 DCK7Y1K Etoposide Breast carcinoma (Cell Line: OCUBM) [5]
Etoposide + MK-1775 DC4LU4S Etoposide Colon carcinoma (Cell Line: RKO) [5]
Everolimus + MK-1775 DC40VKH Everolimus Ewing sarcoma (Cell Line: TC-71) [3]
Exherin + MK-1775 DCT3CJ1 Exherin Ewing sarcoma (Cell Line: TC-71) [3]
Fluorouracil + MK-1775 DC5NCO4 Fluorouracil Breast and ovarian cancer syndrome (Cell Line: UWB1289) [5]
Fluorouracil + MK-1775 DC631VR Fluorouracil Breast carcinoma (Cell Line: KPL1) [5]
Fluorouracil + MK-1775 DCNHKBV Fluorouracil Breast carcinoma (Cell Line: OCUBM) [5]
Fluorouracil + MK-1775 DCPJ54L Fluorouracil Carcinoma (Cell Line: MDAMB436) [5]
Fluorouracil + MK-1775 DCXXE5L Fluorouracil Colon adenocarcinoma (Cell Line: LOVO) [5]
Fluorouracil + MK-1775 DC4JQTY Fluorouracil Colon carcinoma (Cell Line: RKO) [5]
Fluorouracil + MK-1775 DC9P428 Fluorouracil Invasive ductal carcinoma (Cell Line: T-47D) [5]
Fluorouracil + MK-1775 DCMW289 Fluorouracil Rectal adenocarcinoma (Cell Line: SW837) [5]
Fluorouracil + MK-1775 DCWZYKI Fluorouracil Adenocarcinoma (Cell Line: CAOV3) [4]
Fluorouracil + MK-1775 DCWZTBH Fluorouracil Adenocarcinoma (Cell Line: A427) [4]
Fluorouracil + MK-1775 DCQ4T8E Fluorouracil Adenocarcinoma (Cell Line: NCIH2122) [4]
Fluorouracil + MK-1775 DCQ5MYW Fluorouracil Adenocarcinoma (Cell Line: NCIH23) [4]
Fluorouracil + MK-1775 DCTV9MU Fluorouracil Adenocarcinoma (Cell Line: NCIH520) [4]
Fluorouracil + MK-1775 DCE3BWE Fluorouracil Adenocarcinoma (Cell Line: COLO320DM) [4]
Fluorouracil + MK-1775 DC353UD Fluorouracil Adenocarcinoma (Cell Line: HCT116) [4]
Fluorouracil + MK-1775 DCLJJ4D Fluorouracil Adenocarcinoma (Cell Line: HT29) [4]
Fluorouracil + MK-1775 DCWAD6Y Fluorouracil Adenocarcinoma (Cell Line: SW-620) [4]
Fluorouracil + MK-1775 DC5VH5L Fluorouracil Germ cell tumour (Cell Line: PA1) [4]
Fluorouracil + MK-1775 DC00UCH Fluorouracil Malignant melanoma (Cell Line: A375) [4]
Fluorouracil + MK-1775 DCXGTM0 Fluorouracil Malignant melanoma (Cell Line: RPMI7951) [4]
Fluorouracil + MK-1775 DCX73JT Fluorouracil Malignant melanoma (Cell Line: SKMEL30) [4]
Fluorouracil + MK-1775 DC4UY4A Fluorouracil Malignant melanoma (Cell Line: UACC62) [4]
Fluorouracil + MK-1775 DCAZQB6 Fluorouracil Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Fluorouracil + MK-1775 DC3I9NU Fluorouracil Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Fluorouracil + MK-1775 DCUNP29 Fluorouracil Prostate carcinoma (Cell Line: VCAP) [4]
Gemcitabine + MK-1775 DCQ8TLR Gemcitabine Adenocarcinoma (Cell Line: CAOV3) [3]
Gemcitabine + MK-1775 DCX1ABW Gemcitabine Adenocarcinoma (Cell Line: NCIH2122) [3]
Gemcitabine + MK-1775 DCJSNJA Gemcitabine Adenocarcinoma (Cell Line: NCIH520) [3]
Gemcitabine + MK-1775 DCTQC6C Gemcitabine Adenocarcinoma (Cell Line: HT29) [3]
Gemcitabine + MK-1775 DCZTHLV Gemcitabine Germ cell tumour (Cell Line: PA1) [3]
Gemcitabine + MK-1775 DC7TP9G Gemcitabine Malignant melanoma (Cell Line: RPMI7951) [3]
Gemcitabine + MK-1775 DCMJYJF Gemcitabine Malignant melanoma (Cell Line: UACC62) [3]
Gemcitabine + MK-1775 DCNDQON Gemcitabine Prostate carcinoma (Cell Line: VCAP) [3]
Gemcitabine + MK-1775 DC77MHE Gemcitabine Carcinoma (Cell Line: EFM192B) [5]
Gemcitabine + MK-1775 DCN53RS Gemcitabine Invasive ductal carcinoma (Cell Line: T-47D) [5]
Idarubicin + MK-1775 DCNCQMG Idarubicin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Idarubicin + MK-1775 DCNBZAE Idarubicin Breast and ovarian cancer syndrome (Cell Line: UWB1289) [5]
Idarubicin + MK-1775 DCESJGB Idarubicin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
Idarubicin + MK-1775 DCQXID2 Idarubicin Breast carcinoma (Cell Line: OCUBM) [5]
Idarubicin + MK-1775 DC1U2QD Idarubicin Carcinoma (Cell Line: OV90) [5]
Idarubicin + MK-1775 DCEK5FD Idarubicin Carcinoma (Cell Line: EFM192B) [5]
Idarubicin + MK-1775 DCPQH4N Idarubicin Carcinoma (Cell Line: MDAMB436) [5]
Idarubicin + MK-1775 DC1Z1AK Idarubicin Colon adenocarcinoma (Cell Line: LOVO) [5]
Idarubicin + MK-1775 DCVDCXG Idarubicin Invasive ductal carcinoma (Cell Line: T-47D) [5]
Idarubicin + MK-1775 DCX6RFQ Idarubicin Adenocarcinoma (Cell Line: OVCAR3) [4]
Idarubicin + MK-1775 DC28HEO Idarubicin Adenocarcinoma (Cell Line: A427) [4]
Idarubicin + MK-1775 DCTM16L Idarubicin Adenocarcinoma (Cell Line: NCIH1650) [4]
Idarubicin + MK-1775 DCUD797 Idarubicin Adenocarcinoma (Cell Line: NCIH2122) [4]
Idarubicin + MK-1775 DCJGDUJ Idarubicin Adenocarcinoma (Cell Line: NCIH23) [4]
Idarubicin + MK-1775 DCJH09S Idarubicin Adenocarcinoma (Cell Line: COLO320DM) [4]
Idarubicin + MK-1775 DCTU7Z1 Idarubicin Adenocarcinoma (Cell Line: SW-620) [4]
Idarubicin + MK-1775 DCFWILX Idarubicin Amelanotic melanoma (Cell Line: A2058) [4]
Idarubicin + MK-1775 DCWEZ0T Idarubicin Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Idarubicin + MK-1775 DCBGW24 Idarubicin Malignant melanoma (Cell Line: A375) [4]
Idarubicin + MK-1775 DCHA3Z6 Idarubicin Malignant melanoma (Cell Line: RPMI7951) [4]
Idarubicin + MK-1775 DC4PRQ1 Idarubicin Malignant melanoma (Cell Line: UACC62) [4]
Idarubicin + MK-1775 DCT4OGF Idarubicin Mesothelioma (Cell Line: MSTO) [4]
Idarubicin + MK-1775 DCPVB08 Idarubicin Non small cell carcinoma (Cell Line: SKMES1) [4]
Idarubicin + MK-1775 DCWYB3D Idarubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Idarubicin + MK-1775 DCK1LH4 Idarubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Lapatinib + MK-1775 DC1B2O2 Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
Lapatinib + MK-1775 DCG942Q Lapatinib Breast carcinoma (Cell Line: KPL1) [5]
Lapatinib + MK-1775 DCBE7MQ Lapatinib Breast carcinoma (Cell Line: OCUBM) [5]
Lapatinib + MK-1775 DCV0LXB Lapatinib Carcinoma (Cell Line: EFM192B) [5]
Lapatinib + MK-1775 DCWF90P Lapatinib Carcinoma (Cell Line: MDAMB436) [5]
Lapatinib + MK-1775 DCXJ4B4 Lapatinib Colon adenocarcinoma (Cell Line: LOVO) [5]
Lapatinib + MK-1775 DCDQG8R Lapatinib Colon carcinoma (Cell Line: RKO) [5]
Lapatinib + MK-1775 DCVG4BJ Lapatinib Rectal adenocarcinoma (Cell Line: SW837) [5]
Lapatinib + MK-1775 DCWQWWZ Lapatinib Adenocarcinoma (Cell Line: CAOV3) [4]
Lapatinib + MK-1775 DCHK8J8 Lapatinib Adenocarcinoma (Cell Line: A427) [4]
Lapatinib + MK-1775 DC1ZD85 Lapatinib Adenocarcinoma (Cell Line: NCIH2122) [4]
Lapatinib + MK-1775 DCEILRL Lapatinib Adenocarcinoma (Cell Line: NCIH520) [4]
Lapatinib + MK-1775 DC2QLEZ Lapatinib Adenocarcinoma (Cell Line: COLO320DM) [4]
Lapatinib + MK-1775 DCY0VCX Lapatinib Adenocarcinoma (Cell Line: DLD1) [4]
Lapatinib + MK-1775 DCHSU4T Lapatinib Adenocarcinoma (Cell Line: HCT116) [4]
Lapatinib + MK-1775 DCTBR5P Lapatinib Adenocarcinoma (Cell Line: HT29) [4]
Lapatinib + MK-1775 DC21Q7Q Lapatinib Amelanotic melanoma (Cell Line: A2058) [4]
Lapatinib + MK-1775 DCRLKOF Lapatinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Lapatinib + MK-1775 DCQ06O0 Lapatinib Germ cell tumour (Cell Line: PA1) [4]
Lapatinib + MK-1775 DCDY7WK Lapatinib Malignant melanoma (Cell Line: A375) [4]
Lapatinib + MK-1775 DCGE571 Lapatinib Malignant melanoma (Cell Line: HT144) [4]
Lapatinib + MK-1775 DCQJQ3Q Lapatinib Malignant melanoma (Cell Line: RPMI7951) [4]
Lapatinib + MK-1775 DCUDG1U Lapatinib Malignant melanoma (Cell Line: SKMEL30) [4]
Lapatinib + MK-1775 DC79KEQ Lapatinib Malignant melanoma (Cell Line: UACC62) [4]
Lapatinib + MK-1775 DCYTAS1 Lapatinib Mesothelioma (Cell Line: MSTO) [4]
Lapatinib + MK-1775 DCFHHSE Lapatinib Non small cell carcinoma (Cell Line: SKMES1) [4]
Lapatinib + MK-1775 DCQ4R64 Lapatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Lapatinib + MK-1775 DCDIBWQ Lapatinib Prostate carcinoma (Cell Line: VCAP) [4]
Metformin + MK-1775 DCHG1K0 Metformin Adenocarcinoma (Cell Line: OVCAR3) [3]
Metformin + MK-1775 DC5KMKA Metformin Adenocarcinoma (Cell Line: NCIH1650) [3]
Metformin + MK-1775 DC82WND Metformin Adenocarcinoma (Cell Line: NCIH2122) [3]
Metformin + MK-1775 DCP2M11 Metformin Adenocarcinoma (Cell Line: NCIH520) [3]
Metformin + MK-1775 DC80V1O Metformin Adenocarcinoma (Cell Line: HT29) [3]
Metformin + MK-1775 DCKMZT6 Metformin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Metformin + MK-1775 DCQUVN3 Metformin Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Metformin + MK-1775 DCL3ITK Metformin Breast carcinoma (Cell Line: OCUBM) [5]
Methotrexate + MK-1775 DCHHKH2 Methotrexate Adenocarcinoma (Cell Line: OVCAR3) [3]
Methotrexate + MK-1775 DCYGM6J Methotrexate Adenocarcinoma (Cell Line: NCIH23) [3]
Methotrexate + MK-1775 DCNY1KW Methotrexate Adenocarcinoma (Cell Line: HT29) [3]
Methotrexate + MK-1775 DCMGF04 Methotrexate Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Methotrexate + MK-1775 DCA6J41 Methotrexate Invasive ductal carcinoma (Cell Line: T-47D) [5]
Mitomycin + MK-1775 DCK7635 Mitomycin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Mitomycin + MK-1775 DC7RKW8 Mitomycin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
Mitomycin + MK-1775 DCATEAT Mitomycin Breast carcinoma (Cell Line: OCUBM) [5]
Mitomycin + MK-1775 DCQ3H1D Mitomycin Colon adenocarcinoma (Cell Line: LOVO) [5]
Mitomycin + MK-1775 DC8QFU0 Mitomycin Colon carcinoma (Cell Line: RKO) [5]
Mitomycin + MK-1775 DCVV9VP Mitomycin Adenocarcinoma (Cell Line: CAOV3) [4]
Mitomycin + MK-1775 DC4FJT9 Mitomycin Adenocarcinoma (Cell Line: A427) [4]
Mitomycin + MK-1775 DCSX5PI Mitomycin Adenocarcinoma (Cell Line: NCIH2122) [4]
Mitomycin + MK-1775 DCNWPVW Mitomycin Adenocarcinoma (Cell Line: NCIH23) [4]
Mitomycin + MK-1775 DC3O73X Mitomycin Adenocarcinoma (Cell Line: COLO320DM) [4]
Mitomycin + MK-1775 DCJMD43 Mitomycin Adenocarcinoma (Cell Line: HCT116) [4]
Mitomycin + MK-1775 DC9QQIY Mitomycin Adenocarcinoma (Cell Line: HT29) [4]
Mitomycin + MK-1775 DCXJJED Mitomycin Adenocarcinoma (Cell Line: SW-620) [4]
Mitomycin + MK-1775 DCKPEAG Mitomycin Amelanotic melanoma (Cell Line: A2058) [4]
Mitomycin + MK-1775 DCNXV16 Mitomycin Germ cell tumour (Cell Line: PA1) [4]
Mitomycin + MK-1775 DCKUQ53 Mitomycin Malignant melanoma (Cell Line: A375) [4]
Mitomycin + MK-1775 DCIC1O9 Mitomycin Malignant melanoma (Cell Line: RPMI7951) [4]
Mitomycin + MK-1775 DCZNK2N Mitomycin Malignant melanoma (Cell Line: SKMEL30) [4]
Mitomycin + MK-1775 DCFX2QR Mitomycin Mesothelioma (Cell Line: MSTO) [4]
Mitomycin + MK-1775 DCONMV4 Mitomycin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Mitomycin + MK-1775 DC6BYI0 Mitomycin Prostate carcinoma (Cell Line: VCAP) [4]
MK-1775 + Buparlisib DCUI7RF Buparlisib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
MK-1775 + Buparlisib DCJ0YKH Buparlisib Ewing sarcoma (Cell Line: TC-71) [3]
MK-1775 + PD-0325901 DCE76BJ PD-0325901 Adenocarcinoma (Cell Line: CAOV3) [3]
MK-1775 + PD-0325901 DCSX6QD PD-0325901 Adenocarcinoma (Cell Line: NCIH2122) [3]
MK-1775 + PD-0325901 DCXYLII PD-0325901 Adenocarcinoma (Cell Line: DLD1) [3]
MK-1775 + PD-0325901 DC1558R PD-0325901 Hodgkin lymphoma (Cell Line: U-HO1) [3]
MK-1775 + PD-0325901 DCFOLRX PD-0325901 Mesothelioma (Cell Line: MSTO) [3]
MK-1775 + PD-0325901 DCUUTTR PD-0325901 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
MK-1775 + PD-0325901 DCDYWYN PD-0325901 Prostate carcinoma (Cell Line: VCAP) [3]
MK-1775 + Carfilzomib DC9US21 Carfilzomib Ewing sarcoma (Cell Line: TC-71) [3]
MK-1775 + Artemether DCS6Z5Q Artemether Ewing sarcoma (Cell Line: TC-71) [3]
MK-1775 + Ixazomib DCUK2QA Ixazomib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
MK-1775 + RTB101 DCYFEOJ RTB101 Adenocarcinoma (Cell Line: NCIH2122) [3]
MK-1775 + RTB101 DCYBXH5 RTB101 Adenocarcinoma (Cell Line: NCIH520) [3]
MK-1775 + RTB101 DCXSHM2 RTB101 Adenocarcinoma (Cell Line: COLO320DM) [3]
MK-1775 + RTB101 DCU4EYH RTB101 Adenocarcinoma (Cell Line: DLD1) [3]
MK-1775 + RTB101 DCWZQV8 RTB101 Adenocarcinoma (Cell Line: HCT116) [3]
MK-1775 + RTB101 DCZXAT9 RTB101 Adenocarcinoma (Cell Line: HT29) [3]
MK-1775 + RTB101 DC8VZYT RTB101 Adenocarcinoma (Cell Line: SW-620) [3]
MK-1775 + RTB101 DCR0DKK RTB101 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
MK-1775 + RTB101 DCG0FU7 RTB101 Germ cell tumour (Cell Line: PA1) [3]
MK-1775 + RTB101 DCMRDUC RTB101 Malignant melanoma (Cell Line: A375) [3]
MK-1775 + RTB101 DCFOKO1 RTB101 Malignant melanoma (Cell Line: HT144) [3]
MK-1775 + RTB101 DCB5IYJ RTB101 Malignant melanoma (Cell Line: RPMI7951) [3]
MK-1775 + RTB101 DC2TQK3 RTB101 Malignant melanoma (Cell Line: SKMEL30) [3]
MK-1775 + RTB101 DCN9LZK RTB101 Mesothelioma (Cell Line: MSTO) [3]
MK-1775 + RTB101 DCVY5FW RTB101 Non small cell carcinoma (Cell Line: SKMES1) [3]
MK-1775 + RTB101 DC8BRH3 RTB101 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
MK-1775 + RTB101 DCK432M RTB101 Prostate carcinoma (Cell Line: LNCAP) [3]
MK-1775 + RTB101 DCFXWB4 RTB101 Prostate carcinoma (Cell Line: VCAP) [3]
MK-1775 + SCH-900776 DC48JJX SCH-900776 Adenocarcinoma (Cell Line: CAOV3) [3]
MK-1775 + SCH-900776 DC230YQ SCH-900776 Adenocarcinoma (Cell Line: OVCAR3) [3]
MK-1775 + SCH-900776 DCG16WG SCH-900776 Adenocarcinoma (Cell Line: A427) [3]
MK-1775 + SCH-900776 DC7VGCL SCH-900776 Adenocarcinoma (Cell Line: NCIH2122) [3]
MK-1775 + SCH-900776 DCYVKW7 SCH-900776 Adenocarcinoma (Cell Line: NCIH520) [3]
MK-1775 + SCH-900776 DCTWTOL SCH-900776 Adenocarcinoma (Cell Line: COLO320DM) [3]
MK-1775 + SCH-900776 DCIA82B SCH-900776 Adenocarcinoma (Cell Line: DLD1) [3]
MK-1775 + SCH-900776 DCEWOL1 SCH-900776 Adenocarcinoma (Cell Line: HCT116) [3]
MK-1775 + SCH-900776 DCSTMED SCH-900776 Adenocarcinoma (Cell Line: HT29) [3]
MK-1775 + SCH-900776 DCA7ZQN SCH-900776 Amelanotic melanoma (Cell Line: A2058) [3]
MK-1775 + SCH-900776 DCHVP8T SCH-900776 Germ cell tumour (Cell Line: PA1) [3]
MK-1775 + SCH-900776 DC8HG4N SCH-900776 Large cell lung carcinoma (Cell Line: NCI-H460) [3]
MK-1775 + SCH-900776 DCD281V SCH-900776 Malignant melanoma (Cell Line: A375) [3]
MK-1775 + SCH-900776 DC3ECQB SCH-900776 Malignant melanoma (Cell Line: HT144) [3]
MK-1775 + SCH-900776 DC4DUCX SCH-900776 Malignant melanoma (Cell Line: RPMI7951) [3]
MK-1775 + SCH-900776 DC34STB SCH-900776 Malignant melanoma (Cell Line: SKMEL30) [3]
MK-1775 + SCH-900776 DC7RI9T SCH-900776 Mesothelioma (Cell Line: MSTO) [3]
MK-1775 + SCH-900776 DCL0ELV SCH-900776 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
MK-1775 + SCH-900776 DCXSBYW SCH-900776 Prostate carcinoma (Cell Line: VCAP) [3]
MK-1775 + Fomepizole DCR42N8 Fomepizole Ewing sarcoma (Cell Line: TC-71) [3]
MK-1775 + Lenalidomide DCQ1J4M Lenalidomide Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
MK-1775 + AZD8055 DC16FFF AZD8055 Ewing sarcoma (Cell Line: TC-71) [3]
MK-1775 + Formononetin DCZ0WBF Formononetin Ewing sarcoma (Cell Line: TC-71) [3]
MK-1775 + LY2835219 DC6JONG LY2835219 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
MK-1775 + 10-hydroxycamptothecin DCYAV9W 10-hydroxycamptothecin Adenocarcinoma (Cell Line: CAOV3) [3]
MK-1775 + 10-hydroxycamptothecin DCKJVC3 10-hydroxycamptothecin Adenocarcinoma (Cell Line: A427) [3]
MK-1775 + 10-hydroxycamptothecin DCJU6CE 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH1650) [3]
MK-1775 + 10-hydroxycamptothecin DCSFCWT 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH2122) [3]
MK-1775 + 10-hydroxycamptothecin DCT3STD 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH23) [3]
MK-1775 + 10-hydroxycamptothecin DCTACFW 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH520) [3]
MK-1775 + 10-hydroxycamptothecin DCFHGLW 10-hydroxycamptothecin Adenocarcinoma (Cell Line: COLO320DM) [3]
MK-1775 + 10-hydroxycamptothecin DCE8N91 10-hydroxycamptothecin Adenocarcinoma (Cell Line: DLD1) [3]
MK-1775 + 10-hydroxycamptothecin DCLYDCN 10-hydroxycamptothecin Adenocarcinoma (Cell Line: HCT116) [3]
MK-1775 + 10-hydroxycamptothecin DCNBFSS 10-hydroxycamptothecin Adenocarcinoma (Cell Line: HT29) [3]
MK-1775 + 10-hydroxycamptothecin DCMYNM0 10-hydroxycamptothecin Adenocarcinoma (Cell Line: SW-620) [3]
MK-1775 + 10-hydroxycamptothecin DCRBVT9 10-hydroxycamptothecin Amelanotic melanoma (Cell Line: A2058) [3]
MK-1775 + 10-hydroxycamptothecin DC7JN0B 10-hydroxycamptothecin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
MK-1775 + 10-hydroxycamptothecin DCBUPKM 10-hydroxycamptothecin Germ cell tumour (Cell Line: PA1) [3]
MK-1775 + 10-hydroxycamptothecin DCXOCQE 10-hydroxycamptothecin Malignant melanoma (Cell Line: A375) [3]
MK-1775 + 10-hydroxycamptothecin DCOX20A 10-hydroxycamptothecin Malignant melanoma (Cell Line: HT144) [3]
MK-1775 + 10-hydroxycamptothecin DCUFHTV 10-hydroxycamptothecin Malignant melanoma (Cell Line: RPMI7951) [3]
MK-1775 + 10-hydroxycamptothecin DCL12RU 10-hydroxycamptothecin Malignant melanoma (Cell Line: SKMEL30) [3]
MK-1775 + 10-hydroxycamptothecin DC7WTA4 10-hydroxycamptothecin Malignant melanoma (Cell Line: UACC62) [3]
MK-1775 + 10-hydroxycamptothecin DC7F29S 10-hydroxycamptothecin Mesothelioma (Cell Line: MSTO) [3]
MK-1775 + 10-hydroxycamptothecin DCRANYM 10-hydroxycamptothecin Non small cell carcinoma (Cell Line: SKMES1) [3]
MK-1775 + 10-hydroxycamptothecin DCIPYX0 10-hydroxycamptothecin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
MK-1775 + 10-hydroxycamptothecin DCE7JZD 10-hydroxycamptothecin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
MK-1775 + 10-hydroxycamptothecin DCS1873 10-hydroxycamptothecin Prostate carcinoma (Cell Line: LNCAP) [3]
MK-1775 + 10-hydroxycamptothecin DCW7VLR 10-hydroxycamptothecin Prostate carcinoma (Cell Line: VCAP) [3]
MK-1775 + GDC-0084 DCSYH40 GDC-0084 Ewing sarcoma (Cell Line: TC-71) [3]
MK-1775 + Pralatrexate DCA6MCY Pralatrexate Ewing sarcoma (Cell Line: TC-71) [3]
MK-1775 + Pralatrexate DC1OE1P Pralatrexate Hodgkin lymphoma (Cell Line: U-HO1) [3]
MK-1775 + SNX-2112 DC9F99K SNX-2112 Adenocarcinoma (Cell Line: OVCAR3) [3]
MK-1775 + SNX-2112 DCJRSKJ SNX-2112 Adenocarcinoma (Cell Line: COLO320DM) [3]
MK-1775 + SNX-2112 DCR5JTN SNX-2112 Adenocarcinoma (Cell Line: DLD1) [3]
MK-1775 + SNX-2112 DCB8F4X SNX-2112 Adenocarcinoma (Cell Line: HCT116) [3]
MK-1775 + SNX-2112 DC0TTTP SNX-2112 Adenocarcinoma (Cell Line: SW-620) [3]
MK-1775 + SNX-2112 DCNDPZY SNX-2112 Amelanotic melanoma (Cell Line: A2058) [3]
MK-1775 + SNX-2112 DC5488Q SNX-2112 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
MK-1775 + SNX-2112 DC3DD90 SNX-2112 Germ cell tumour (Cell Line: PA1) [3]
MK-1775 + SNX-2112 DCNMHLY SNX-2112 Large cell lung carcinoma (Cell Line: NCI-H460) [3]
MK-1775 + SNX-2112 DC1XKAO SNX-2112 Malignant melanoma (Cell Line: RPMI7951) [3]
MK-1775 + SNX-2112 DCPFJWS SNX-2112 Malignant melanoma (Cell Line: SKMEL30) [3]
MK-1775 + SNX-2112 DCPHBT5 SNX-2112 Mesothelioma (Cell Line: MSTO) [3]
MK-1775 + SNX-2112 DCRP09O SNX-2112 Non small cell carcinoma (Cell Line: SKMES1) [3]
MK-1775 + SNX-2112 DCIQ3QC SNX-2112 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
MK-1775 + SNX-2112 DCJ2KSI SNX-2112 Prostate carcinoma (Cell Line: VCAP) [3]
MK-1775 + Selumetinib DCK6Z2R Selumetinib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
MK-1775 + Erlotinib DC92V49 Erlotinib Adenocarcinoma (Cell Line: CAOV3) [3]
MK-1775 + Erlotinib DCTO1SJ Erlotinib Adenocarcinoma (Cell Line: NCIH1650) [3]
MK-1775 + Erlotinib DCEZJXP Erlotinib Adenocarcinoma (Cell Line: NCIH2122) [3]
MK-1775 + Erlotinib DCK3IEP Erlotinib Adenocarcinoma (Cell Line: NCIH520) [3]
MK-1775 + Erlotinib DCDA56W Erlotinib Adenocarcinoma (Cell Line: COLO320DM) [3]
MK-1775 + Erlotinib DCMFK7Q Erlotinib Adenocarcinoma (Cell Line: HCT116) [3]
MK-1775 + Erlotinib DCJ3FI1 Erlotinib Adenocarcinoma (Cell Line: HT29) [3]
MK-1775 + Erlotinib DCHY8DA Erlotinib Adenocarcinoma (Cell Line: SW-620) [3]
MK-1775 + Erlotinib DC7CN19 Erlotinib Amelanotic melanoma (Cell Line: A2058) [3]
MK-1775 + Erlotinib DCVEAFS Erlotinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
MK-1775 + Erlotinib DCKPLK7 Erlotinib Germ cell tumour (Cell Line: PA1) [3]
MK-1775 + Erlotinib DC8JI6U Erlotinib Large cell lung carcinoma (Cell Line: NCI-H460) [3]
MK-1775 + Erlotinib DCOEWRR Erlotinib Malignant melanoma (Cell Line: A375) [3]
MK-1775 + Erlotinib DC45ENQ Erlotinib Malignant melanoma (Cell Line: SKMEL30) [3]
MK-1775 + Erlotinib DCMV16H Erlotinib Malignant melanoma (Cell Line: UACC62) [3]
MK-1775 + Erlotinib DC9QV02 Erlotinib Mesothelioma (Cell Line: MSTO) [3]
MK-1775 + Erlotinib DCEG4FJ Erlotinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
MK-1775 + Erlotinib DCWS8F2 Erlotinib Prostate carcinoma (Cell Line: VCAP) [3]
MK-1775 + Daporinad DCZ1UOA Daporinad Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
MK-1775 + Plinabulin DC75EQG Plinabulin Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
MK-1775 + Docetaxel DCJ5WF6 Docetaxel Ewing sarcoma (Cell Line: TC-71) [3]
MK-1775 + THAPSIGARGIN DCS3FO4 THAPSIGARGIN Ewing sarcoma (Cell Line: TC-71) [3]
MK-1775 + Etoposide DCPNVCG Etoposide Ewing sarcoma (Cell Line: TC-71) [3]
MK-1775 + Etoposide DCTV6RJ Etoposide Hodgkin lymphoma (Cell Line: U-HO1) [3]
MK-1775 + AEE-788 DCCQCNC AEE-788 Ewing sarcoma (Cell Line: TC-71) [3]
MK-1775 + Cycloheximide DCY6ZZ4 Cycloheximide Ewing sarcoma (Cell Line: TC-71) [3]
MK-1775 + Mitomycin DC9DB2U Mitomycin Ewing sarcoma (Cell Line: TC-71) [3]
MK-1775 + OSI-906 DCSUMSL OSI-906 Ewing sarcoma (Cell Line: TC-71) [3]
MK-1775 + Vincristine DC0PERD Vincristine Ewing sarcoma (Cell Line: TC-71) [3]
MK-1775 + Ridaforolimus DCT7IN2 Ridaforolimus Adenocarcinoma (Cell Line: CAOV3) [3]
MK-1775 + Ridaforolimus DCS8YOH Ridaforolimus Adenocarcinoma (Cell Line: NCIH2122) [3]
MK-1775 + Ridaforolimus DC52I6V Ridaforolimus Adenocarcinoma (Cell Line: HCT116) [3]
MK-1775 + Ridaforolimus DCU728B Ridaforolimus Adenocarcinoma (Cell Line: HT29) [3]
MK-1775 + Ridaforolimus DCFRRQC Ridaforolimus Amelanotic melanoma (Cell Line: A2058) [3]
MK-1775 + Ridaforolimus DCJXCKO Ridaforolimus Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
MK-1775 + Ridaforolimus DCMVRXJ Ridaforolimus Germ cell tumour (Cell Line: PA1) [3]
MK-1775 + Ridaforolimus DCGA5J7 Ridaforolimus Malignant melanoma (Cell Line: A375) [3]
MK-1775 + Ridaforolimus DCPG0HL Ridaforolimus Malignant melanoma (Cell Line: SKMEL30) [3]
MK-1775 + Ridaforolimus DCZRS2V Ridaforolimus Mesothelioma (Cell Line: MSTO) [3]
MK-1775 + Ridaforolimus DCMF756 Ridaforolimus Non small cell carcinoma (Cell Line: SKMES1) [3]
MK-1775 + Ridaforolimus DC5YV74 Ridaforolimus Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
MK-1775 + Ridaforolimus DCX10HL Ridaforolimus Prostate carcinoma (Cell Line: LNCAP) [3]
MK-1775 + Ridaforolimus DCOSCKI Ridaforolimus Prostate carcinoma (Cell Line: VCAP) [3]
MK-1775 + MK-4827 DCS4AFH MK-4827 Adenocarcinoma (Cell Line: OVCAR3) [3]
MK-1775 + MK-4827 DCZJ0WT MK-4827 Adenocarcinoma (Cell Line: A427) [3]
MK-1775 + MK-4827 DCUOZ58 MK-4827 Adenocarcinoma (Cell Line: NCIH2122) [3]
MK-1775 + MK-4827 DCUXGOA MK-4827 Adenocarcinoma (Cell Line: NCIH23) [3]
MK-1775 + MK-4827 DCIAJFG MK-4827 Adenocarcinoma (Cell Line: NCIH520) [3]
MK-1775 + MK-4827 DC1H17C MK-4827 Adenocarcinoma (Cell Line: COLO320DM) [3]
MK-1775 + MK-4827 DCV06I1 MK-4827 Adenocarcinoma (Cell Line: HCT116) [3]
MK-1775 + MK-4827 DCQH4L2 MK-4827 Adenocarcinoma (Cell Line: HT29) [3]
MK-1775 + MK-4827 DCXKP27 MK-4827 Adenocarcinoma (Cell Line: SW-620) [3]
MK-1775 + MK-4827 DCB756T MK-4827 Amelanotic melanoma (Cell Line: A2058) [3]
MK-1775 + MK-4827 DC789LA MK-4827 Germ cell tumour (Cell Line: PA1) [3]
MK-1775 + MK-4827 DCOT6P6 MK-4827 Large cell lung carcinoma (Cell Line: NCI-H460) [3]
MK-1775 + MK-4827 DC1K916 MK-4827 Malignant melanoma (Cell Line: A375) [3]
MK-1775 + MK-4827 DCZ0GA3 MK-4827 Malignant melanoma (Cell Line: RPMI7951) [3]
MK-1775 + MK-4827 DCXL4GW MK-4827 Malignant melanoma (Cell Line: SKMEL30) [3]
MK-1775 + MK-4827 DCSSQGR MK-4827 Non small cell carcinoma (Cell Line: SKMES1) [3]
MK-1775 + MK-4827 DCEX7IO MK-4827 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
MK-1775 + MK-4827 DC8UK48 MK-4827 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
MK-1775 + MK-4827 DC94MO2 MK-4827 Prostate carcinoma (Cell Line: LNCAP) [3]
MK-1775 + MK-4827 DCP6R64 MK-4827 Prostate carcinoma (Cell Line: VCAP) [3]
MK-1775 + Lomustine DC66PPQ Lomustine Adenocarcinoma (Cell Line: NCIH2122) [3]
MK-1775 + Lomustine DCVCRTV Lomustine Adenocarcinoma (Cell Line: COLO320DM) [3]
MK-1775 + Lomustine DCCR8BU Lomustine Adenocarcinoma (Cell Line: HCT116) [3]
MK-1775 + Lomustine DCVLUHK Lomustine Adenocarcinoma (Cell Line: HT29) [3]
MK-1775 + Lomustine DCPEGKM Lomustine Adenocarcinoma (Cell Line: SW-620) [3]
MK-1775 + Lomustine DCATC9J Lomustine Amelanotic melanoma (Cell Line: A2058) [3]
MK-1775 + Lomustine DC3TO8I Lomustine Malignant melanoma (Cell Line: A375) [3]
MK-1775 + Lomustine DCUFY1O Lomustine Malignant melanoma (Cell Line: SKMEL30) [3]
MK-1775 + Lomustine DC0R7FE Lomustine Mesothelioma (Cell Line: MSTO) [3]
MK-1775 + Lomustine DC68WMK Lomustine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
MK-1775 + Lomustine DC23GGY Lomustine Prostate carcinoma (Cell Line: LNCAP) [3]
MK-1775 + Lomustine DCX8T8L Lomustine Prostate carcinoma (Cell Line: VCAP) [3]
MK-1775 + Bortezomib DC95KVY Bortezomib Adenocarcinoma (Cell Line: A427) [3]
MK-1775 + Bortezomib DCBLT1Y Bortezomib Adenocarcinoma (Cell Line: NCIH2122) [3]
MK-1775 + Bortezomib DC55GOH Bortezomib Adenocarcinoma (Cell Line: COLO320DM) [3]
MK-1775 + Bortezomib DCJH1GZ Bortezomib Adenocarcinoma (Cell Line: HT29) [3]
MK-1775 + Bortezomib DCZ7HEJ Bortezomib Adenocarcinoma (Cell Line: SW-620) [3]
MK-1775 + Bortezomib DCKAAZK Bortezomib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
MK-1775 + Bortezomib DCF99WB Bortezomib Malignant melanoma (Cell Line: RPMI7951) [3]
MK-1775 + Bortezomib DCS42M7 Bortezomib Malignant melanoma (Cell Line: SKMEL30) [3]
MK-1775 + Bortezomib DCNOE2F Bortezomib Malignant melanoma (Cell Line: UACC62) [3]
MK-1775 + Bortezomib DCT54QQ Bortezomib Mesothelioma (Cell Line: MSTO) [3]
MK-1775 + Bortezomib DCI9PTW Bortezomib Non small cell carcinoma (Cell Line: SKMES1) [3]
MK-1775 + Bortezomib DCF09Z3 Bortezomib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
MK-1775 + Bardoxolone methyl DC2F2UE Bardoxolone methyl Hodgkin lymphoma (Cell Line: U-HO1) [3]
MK-1775 + Ispinesib DC65RBT Ispinesib Ewing sarcoma (Cell Line: TC-71) [3]
MK-1775 + GSK525762 DCZ9JNY GSK525762 Adenocarcinoma (Cell Line: OVCAR3) [3]
MK-1775 + BMS-754807 DC7HRPI BMS-754807 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
MK-1775 + Decitabine DC0FTSA Decitabine Ewing sarcoma (Cell Line: TC-71) [3]
MK-1775 + Sorafenib DCL1V7Z Sorafenib Adenocarcinoma (Cell Line: OVCAR3) [3]
MK-1775 + Sorafenib DCPDEFK Sorafenib Adenocarcinoma (Cell Line: NCIH520) [3]
MK-1775 + Sorafenib DCIP4TF Sorafenib Adenocarcinoma (Cell Line: DLD1) [3]
MK-1775 + Sorafenib DCT8WYP Sorafenib Adenocarcinoma (Cell Line: HCT116) [3]
MK-1775 + Sorafenib DCHC4Z3 Sorafenib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
MK-1775 + Sorafenib DCOBIGC Sorafenib Germ cell tumour (Cell Line: PA1) [3]
MK-1775 + Sorafenib DCXA45N Sorafenib Malignant melanoma (Cell Line: A375) [3]
MK-1775 + Sorafenib DCME7R0 Sorafenib Malignant melanoma (Cell Line: HT144) [3]
MK-1775 + Sorafenib DC9PTZ7 Sorafenib Malignant melanoma (Cell Line: SKMEL30) [3]
MK-1775 + Sorafenib DCWRI9F Sorafenib Malignant melanoma (Cell Line: UACC62) [3]
MK-1775 + Sorafenib DCGCMO5 Sorafenib Mesothelioma (Cell Line: MSTO) [3]
MK-1775 + Sorafenib DC143D3 Sorafenib Non small cell carcinoma (Cell Line: SKMES1) [3]
MK-1775 + Sorafenib DCL1G3T Sorafenib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
MK-1775 + Sorafenib DCUTN1D Sorafenib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
MK-1775 + PF-562271 DCBFAPA PF-562271 Hodgkin lymphoma (Cell Line: U-HO1) [3]
MK-1775 + MK-2206 DCFC43W MK-2206 Adenocarcinoma (Cell Line: CAOV3) [3]
MK-1775 + MK-2206 DCCO6X0 MK-2206 Adenocarcinoma (Cell Line: A427) [3]
MK-1775 + MK-2206 DC7JPOQ MK-2206 Adenocarcinoma (Cell Line: NCIH2122) [3]
MK-1775 + MK-2206 DCPF5PE MK-2206 Adenocarcinoma (Cell Line: NCIH23) [3]
MK-1775 + MK-2206 DC369HV MK-2206 Adenocarcinoma (Cell Line: NCIH520) [3]
MK-1775 + MK-2206 DC52IWZ MK-2206 Adenocarcinoma (Cell Line: COLO320DM) [3]
MK-1775 + MK-2206 DCQHCN2 MK-2206 Adenocarcinoma (Cell Line: HCT116) [3]
MK-1775 + MK-2206 DCQJKT4 MK-2206 Adenocarcinoma (Cell Line: HT29) [3]
MK-1775 + MK-2206 DCYS0LN MK-2206 Adenocarcinoma (Cell Line: SW-620) [3]
MK-1775 + MK-2206 DCPZ8QH MK-2206 Amelanotic melanoma (Cell Line: A2058) [3]
MK-1775 + MK-2206 DC3JZJ4 MK-2206 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
MK-1775 + MK-2206 DC3R8WO MK-2206 Germ cell tumour (Cell Line: PA1) [3]
MK-1775 + MK-2206 DCB8UL3 MK-2206 Large cell lung carcinoma (Cell Line: NCI-H460) [3]
MK-1775 + MK-2206 DCXGS5G MK-2206 Malignant melanoma (Cell Line: A375) [3]
MK-1775 + MK-2206 DCI0AK7 MK-2206 Malignant melanoma (Cell Line: RPMI7951) [3]
MK-1775 + MK-2206 DCAUF9J MK-2206 Malignant melanoma (Cell Line: SKMEL30) [3]
MK-1775 + MK-2206 DCOP21X MK-2206 Malignant melanoma (Cell Line: UACC62) [3]
MK-1775 + MK-2206 DCK8X1R MK-2206 Non small cell carcinoma (Cell Line: SKMES1) [3]
MK-1775 + MK-2206 DCDJCT3 MK-2206 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
MK-1775 + MK-2206 DC9S7QC MK-2206 Prostate carcinoma (Cell Line: VCAP) [3]
MK-1775 + Romidepsin DC1I7YU Romidepsin Ewing sarcoma (Cell Line: TC-71) [3]
MK-1775 + CHS-828 DCUMDKR CHS-828 Ewing sarcoma (Cell Line: TC-71) [3]
MK-1775 + NVP-AUY922 DCWJYMY NVP-AUY922 Ewing sarcoma (Cell Line: TC-71) [3]
MK-1775 + AZD8330 DC9EKIB AZD8330 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
MK-1775 + Doxorubicin DCLAEWE Doxorubicin Ewing sarcoma (Cell Line: TC-71) [3]
MK-1775 + Vorinostat DC2YOAN Vorinostat Adenocarcinoma (Cell Line: CAOV3) [3]
MK-1775 + Vorinostat DCFOEF8 Vorinostat Adenocarcinoma (Cell Line: NCIH2122) [3]
MK-1775 + Vorinostat DCA5L2F Vorinostat Adenocarcinoma (Cell Line: NCIH23) [3]
MK-1775 + Vorinostat DCLTDUS Vorinostat Adenocarcinoma (Cell Line: NCIH520) [3]
MK-1775 + Vorinostat DC5QXMU Vorinostat Adenocarcinoma (Cell Line: COLO320DM) [3]
MK-1775 + Vorinostat DC38FI7 Vorinostat Adenocarcinoma (Cell Line: DLD1) [3]
MK-1775 + Vorinostat DCATNB5 Vorinostat Adenocarcinoma (Cell Line: HCT116) [3]
MK-1775 + Vorinostat DCUCXMF Vorinostat Adenocarcinoma (Cell Line: HT29) [3]
MK-1775 + Vorinostat DC550KZ Vorinostat Amelanotic melanoma (Cell Line: A2058) [3]
MK-1775 + Vorinostat DC2FGVX Vorinostat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
MK-1775 + Vorinostat DCK35VP Vorinostat Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
MK-1775 + Vorinostat DCINHCD Vorinostat Germ cell tumour (Cell Line: PA1) [3]
MK-1775 + Vorinostat DC2XHKH Vorinostat Large cell lung carcinoma (Cell Line: NCI-H460) [3]
MK-1775 + Vorinostat DCP0V28 Vorinostat Malignant melanoma (Cell Line: A375) [3]
MK-1775 + Vorinostat DCNALVK Vorinostat Malignant melanoma (Cell Line: RPMI7951) [3]
MK-1775 + Vorinostat DCXER2J Vorinostat Malignant melanoma (Cell Line: SKMEL30) [3]
MK-1775 + Vorinostat DCMC327 Vorinostat Mesothelioma (Cell Line: MSTO) [3]
MK-1775 + Vorinostat DCKQQTA Vorinostat Non small cell carcinoma (Cell Line: SKMES1) [3]
MK-1775 + Vorinostat DCYHZFO Vorinostat Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
MK-1775 + Vorinostat DCI5C9V Vorinostat Prostate carcinoma (Cell Line: VCAP) [3]
MK-1775 + Dasatinib DCBK4TC Dasatinib Adenocarcinoma (Cell Line: OVCAR3) [3]
MK-1775 + Dasatinib DC2BAIJ Dasatinib Adenocarcinoma (Cell Line: A427) [3]
MK-1775 + Dasatinib DCPCIOP Dasatinib Adenocarcinoma (Cell Line: NCIH520) [3]
MK-1775 + Dasatinib DCI9ORQ Dasatinib Adenocarcinoma (Cell Line: COLO320DM) [3]
MK-1775 + Dasatinib DC4XX4A Dasatinib Adenocarcinoma (Cell Line: DLD1) [3]
MK-1775 + Dasatinib DCW3TM8 Dasatinib Adenocarcinoma (Cell Line: HT29) [3]
MK-1775 + Dasatinib DCS4H28 Dasatinib Adenocarcinoma (Cell Line: SW-620) [3]
MK-1775 + Dasatinib DCS1RPI Dasatinib Germ cell tumour (Cell Line: PA1) [3]
MK-1775 + Dasatinib DCTWNDY Dasatinib Malignant melanoma (Cell Line: A375) [3]
MK-1775 + Dasatinib DCLS3W5 Dasatinib Malignant melanoma (Cell Line: RPMI7951) [3]
MK-1775 + Dasatinib DCWU01F Dasatinib Mesothelioma (Cell Line: MSTO) [3]
MK-1775 + Dasatinib DCN716R Dasatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
MK-1775 + Cytarabine DC42N3Q Cytarabine Ewing sarcoma (Cell Line: TC-71) [3]
MK-1775 + PD-0325901 DCJNFVQ PD-0325901 Breast carcinoma (Cell Line: OCUBM) [5]
MK-1775 + PD-0325901 DC0HRUI PD-0325901 Carcinoma (Cell Line: EFM192B) [5]
MK-1775 + PD-0325901 DCYBYGQ PD-0325901 Invasive ductal carcinoma (Cell Line: T-47D) [5]
MK-1775 + RTB101 DCXGPKA RTB101 Breast carcinoma (Cell Line: ZR751) [5]
MK-1775 + RTB101 DC0HHQV RTB101 Breast carcinoma (Cell Line: OCUBM) [5]
MK-1775 + RTB101 DCPXFEZ RTB101 Carcinoma (Cell Line: EFM192B) [5]
MK-1775 + RTB101 DCLY0HZ RTB101 Carcinoma (Cell Line: MDAMB436) [5]
MK-1775 + RTB101 DC1BAGP RTB101 Colon adenocarcinoma (Cell Line: LOVO) [5]
MK-1775 + RTB101 DCYH32Q RTB101 Colon carcinoma (Cell Line: RKO) [5]
MK-1775 + RTB101 DCDU3HX RTB101 Invasive ductal carcinoma (Cell Line: T-47D) [5]
MK-1775 + SCH-900776 DCWS3AK SCH-900776 Breast carcinoma (Cell Line: ZR751) [5]
MK-1775 + SCH-900776 DC4F2BU SCH-900776 Breast carcinoma (Cell Line: OCUBM) [5]
MK-1775 + SCH-900776 DC06G64 SCH-900776 Carcinoma (Cell Line: OV90) [5]
MK-1775 + SCH-900776 DC3AKDF SCH-900776 Colon carcinoma (Cell Line: RKO) [5]
MK-1775 + SCH-900776 DC89Z74 SCH-900776 Invasive ductal carcinoma (Cell Line: T-47D) [5]
MK-1775 + 10-hydroxycamptothecin DCAIH7B 10-hydroxycamptothecin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
MK-1775 + 10-hydroxycamptothecin DCQITCE 10-hydroxycamptothecin Breast carcinoma (Cell Line: ZR751) [5]
MK-1775 + 10-hydroxycamptothecin DCR4NH7 10-hydroxycamptothecin Breast carcinoma (Cell Line: KPL1) [5]
MK-1775 + 10-hydroxycamptothecin DCEVLLZ 10-hydroxycamptothecin Breast carcinoma (Cell Line: OCUBM) [5]
MK-1775 + 10-hydroxycamptothecin DCD287V 10-hydroxycamptothecin Carcinoma (Cell Line: OV90) [5]
MK-1775 + 10-hydroxycamptothecin DCLK4KW 10-hydroxycamptothecin Carcinoma (Cell Line: EFM192B) [5]
MK-1775 + 10-hydroxycamptothecin DCY5C8B 10-hydroxycamptothecin Colon adenocarcinoma (Cell Line: LOVO) [5]
MK-1775 + 10-hydroxycamptothecin DC0R11T 10-hydroxycamptothecin Colon carcinoma (Cell Line: RKO) [5]
MK-1775 + 10-hydroxycamptothecin DCZOGE0 10-hydroxycamptothecin Invasive ductal carcinoma (Cell Line: T-47D) [5]
MK-1775 + SNX-2112 DC1YOJN SNX-2112 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [5]
MK-1775 + SNX-2112 DCK7EQI SNX-2112 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
MK-1775 + SNX-2112 DCZJPC2 SNX-2112 Breast carcinoma (Cell Line: OCUBM) [5]
MK-1775 + SNX-2112 DC58QG1 SNX-2112 Carcinoma (Cell Line: EFM192B) [5]
MK-1775 + SNX-2112 DCTN716 SNX-2112 Colon adenocarcinoma (Cell Line: LOVO) [5]
MK-1775 + SNX-2112 DCUD15Z SNX-2112 Colon carcinoma (Cell Line: RKO) [5]
MK-1775 + SNX-2112 DCRJJBK SNX-2112 Invasive ductal carcinoma (Cell Line: T-47D) [5]
MK-1775 + Erlotinib DCVTOT1 Erlotinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
MK-1775 + Erlotinib DCBHNVH Erlotinib Breast carcinoma (Cell Line: KPL1) [5]
MK-1775 + Erlotinib DCKLEMV Erlotinib Breast carcinoma (Cell Line: OCUBM) [5]
MK-1775 + Erlotinib DCZLMSY Erlotinib Carcinoma (Cell Line: EFM192B) [5]
MK-1775 + Erlotinib DCANMCQ Erlotinib Colon adenocarcinoma (Cell Line: LOVO) [5]
MK-1775 + Erlotinib DCVL1HK Erlotinib Colon carcinoma (Cell Line: RKO) [5]
MK-1775 + Erlotinib DCFIU4D Erlotinib Rectal adenocarcinoma (Cell Line: SW837) [5]
MK-1775 + Ridaforolimus DC0IBEJ Ridaforolimus Breast carcinoma (Cell Line: KPL1) [5]
MK-1775 + Ridaforolimus DCI0DOY Ridaforolimus Colon adenocarcinoma (Cell Line: LOVO) [5]
MK-1775 + Ridaforolimus DCYKCYG Ridaforolimus Colon carcinoma (Cell Line: RKO) [5]
MK-1775 + MK-4827 DCMMN8B MK-4827 Breast carcinoma (Cell Line: ZR751) [5]
MK-1775 + MK-4827 DCPCLUJ MK-4827 Breast carcinoma (Cell Line: KPL1) [5]
MK-1775 + MK-4827 DCBUPX3 MK-4827 Breast carcinoma (Cell Line: OCUBM) [5]
MK-1775 + MK-4827 DC0IWEK MK-4827 Carcinoma (Cell Line: EFM192B) [5]
MK-1775 + MK-4827 DC6J8HT MK-4827 Colon adenocarcinoma (Cell Line: LOVO) [5]
MK-1775 + MK-4827 DC39R1W MK-4827 Colon carcinoma (Cell Line: RKO) [5]
MK-1775 + MK-4827 DCB4CSV MK-4827 Invasive ductal carcinoma (Cell Line: T-47D) [5]
MK-1775 + MK-4827 DC03UAA MK-4827 Rectal adenocarcinoma (Cell Line: SW837) [5]
MK-1775 + Lomustine DCUP87O Lomustine Breast carcinoma (Cell Line: KPL1) [5]
MK-1775 + Lomustine DC496QF Lomustine Breast carcinoma (Cell Line: OCUBM) [5]
MK-1775 + Lomustine DCQLKJA Lomustine Carcinoma (Cell Line: EFM192B) [5]
MK-1775 + Lomustine DCDDTV0 Lomustine Colon carcinoma (Cell Line: RKO) [5]
MK-1775 + Bortezomib DCM5GJK Bortezomib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [5]
MK-1775 + Bortezomib DC4SF4C Bortezomib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
MK-1775 + Bortezomib DCMTJ7X Bortezomib Breast carcinoma (Cell Line: ZR751) [5]
MK-1775 + Bortezomib DCHJWN9 Bortezomib Breast carcinoma (Cell Line: OCUBM) [5]
MK-1775 + Bortezomib DCZG84X Bortezomib Carcinoma (Cell Line: EFM192B) [5]
MK-1775 + Bortezomib DCCJ2UW Bortezomib Carcinoma (Cell Line: MDAMB436) [5]
MK-1775 + Bortezomib DC4JPT4 Bortezomib Colon carcinoma (Cell Line: RKO) [5]
MK-1775 + GSK525762 DCK7PJ9 GSK525762 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
MK-1775 + GSK525762 DC4CW9F GSK525762 Colon carcinoma (Cell Line: RKO) [5]
MK-1775 + GSK525762 DC6K20C GSK525762 Invasive ductal carcinoma (Cell Line: T-47D) [5]
MK-1775 + Sorafenib DCXTVMS Sorafenib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
MK-1775 + Sorafenib DCOB8GX Sorafenib Breast carcinoma (Cell Line: ZR751) [5]
MK-1775 + Sorafenib DCUBPCR Sorafenib Breast carcinoma (Cell Line: OCUBM) [5]
MK-1775 + Sorafenib DCOHX3C Sorafenib Colon carcinoma (Cell Line: RKO) [5]
MK-1775 + Sorafenib DCK9YXT Sorafenib Invasive ductal carcinoma (Cell Line: T-47D) [5]
MK-1775 + MK-2206 DCHT9J8 MK-2206 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [5]
MK-1775 + MK-2206 DC2MXPD MK-2206 Breast carcinoma (Cell Line: KPL1) [5]
MK-1775 + MK-2206 DCCFBFL MK-2206 Breast carcinoma (Cell Line: OCUBM) [5]
MK-1775 + MK-2206 DCIIOM2 MK-2206 Carcinoma (Cell Line: MDAMB436) [5]
MK-1775 + MK-2206 DCQ1TMN MK-2206 Colon carcinoma (Cell Line: RKO) [5]
MK-1775 + MK-2206 DCY9QLV MK-2206 Invasive ductal carcinoma (Cell Line: T-47D) [5]
MK-1775 + MK-2206 DCQ8DJH MK-2206 Rectal adenocarcinoma (Cell Line: SW837) [5]
MK-1775 + Vorinostat DCCVQIT Vorinostat Colon adenocarcinoma (Cell Line: LOVO) [5]
MK-1775 + Vorinostat DCUHNEO Vorinostat Colon carcinoma (Cell Line: RKO) [5]
MK-1775 + Dasatinib DCV6ZA0 Dasatinib Breast carcinoma (Cell Line: ZR751) [5]
MK-1775 + Dasatinib DCBAEKF Dasatinib Breast carcinoma (Cell Line: KPL1) [5]
MK-1775 + Dasatinib DC4HIXA Dasatinib Breast carcinoma (Cell Line: OCUBM) [5]
MK-1775 + Dasatinib DCPQITR Dasatinib Colon carcinoma (Cell Line: RKO) [5]
MK-2206 + MK-1775 DC90LHD MK-2206 Ewing sarcoma (Cell Line: TC-71) [3]
MK-5108 + MK-1775 DCDQSUA MK-5108 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
MK-5108 + MK-1775 DCRX11K MK-5108 Breast carcinoma (Cell Line: OCUBM) [5]
MK-5108 + MK-1775 DC56HD2 MK-5108 Carcinoma (Cell Line: MDAMB436) [5]
MK-5108 + MK-1775 DCABBSQ MK-5108 Colon carcinoma (Cell Line: RKO) [5]
MK-5108 + MK-1775 DCYYN7D MK-5108 Invasive ductal carcinoma (Cell Line: T-47D) [5]
MK-5108 + MK-1775 DCUSAYP MK-5108 Rectal adenocarcinoma (Cell Line: SW837) [5]
MK-5108 + MK-1775 DCOXEVO MK-5108 Adenocarcinoma (Cell Line: CAOV3) [4]
MK-5108 + MK-1775 DC44MSQ MK-5108 Adenocarcinoma (Cell Line: OVCAR3) [4]
MK-5108 + MK-1775 DCSO3XW MK-5108 Adenocarcinoma (Cell Line: A427) [4]
MK-5108 + MK-1775 DCC7BQ6 MK-5108 Adenocarcinoma (Cell Line: NCIH2122) [4]
MK-5108 + MK-1775 DCN623R MK-5108 Adenocarcinoma (Cell Line: NCIH23) [4]
MK-5108 + MK-1775 DCGQ7NR MK-5108 Adenocarcinoma (Cell Line: COLO320DM) [4]
MK-5108 + MK-1775 DC2M4QD MK-5108 Adenocarcinoma (Cell Line: HCT116) [4]
MK-5108 + MK-1775 DCUWAYC MK-5108 Adenocarcinoma (Cell Line: HT29) [4]
MK-5108 + MK-1775 DCBPBOT MK-5108 Adenocarcinoma (Cell Line: SW-620) [4]
MK-5108 + MK-1775 DCFA5RP MK-5108 Amelanotic melanoma (Cell Line: A2058) [4]
MK-5108 + MK-1775 DCIUM2S MK-5108 Germ cell tumour (Cell Line: PA1) [4]
MK-5108 + MK-1775 DCFSZYW MK-5108 Malignant melanoma (Cell Line: A375) [4]
MK-5108 + MK-1775 DCE0O1S MK-5108 Malignant melanoma (Cell Line: RPMI7951) [4]
MK-5108 + MK-1775 DCH60AA MK-5108 Malignant melanoma (Cell Line: SKMEL30) [4]
MK-5108 + MK-1775 DC45SSS MK-5108 Malignant melanoma (Cell Line: UACC62) [4]
MK-5108 + MK-1775 DCBDDWF MK-5108 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
MK-5108 + MK-1775 DC7SDXK MK-5108 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
MK-5108 + MK-1775 DC3W8HM MK-5108 Prostate carcinoma (Cell Line: VCAP) [4]
OSI-027 + MK-1775 DCLRWH0 OSI-027 Hodgkin lymphoma (Cell Line: U-HO1) [3]
Panobinostat + MK-1775 DCBAO7V Panobinostat Ewing sarcoma (Cell Line: TC-71) [3]
PD-0325901 + MK-1775 DCODYQX PD-0325901 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
PD-0325901 + MK-1775 DC7O6JW PD-0325901 Breast carcinoma (Cell Line: KPL1) [5]
PD-0325901 + MK-1775 DC7OQUQ PD-0325901 Breast carcinoma (Cell Line: OCUBM) [5]
PD-0325901 + MK-1775 DCTK7SR PD-0325901 Carcinoma (Cell Line: OV90) [5]
PD-0325901 + MK-1775 DCI5H81 PD-0325901 Carcinoma (Cell Line: EFM192B) [5]
PD-0325901 + MK-1775 DCRYJXE PD-0325901 Carcinoma (Cell Line: MDAMB436) [5]
PD-0325901 + MK-1775 DC5DWQJ PD-0325901 Colon adenocarcinoma (Cell Line: LOVO) [5]
PD-0325901 + MK-1775 DCPUR97 PD-0325901 Colon carcinoma (Cell Line: RKO) [5]
PD-0325901 + MK-1775 DCKVWNX PD-0325901 Invasive ductal carcinoma (Cell Line: T-47D) [5]
PD-0325901 + MK-1775 DCTQ4YH PD-0325901 Rectal adenocarcinoma (Cell Line: SW837) [5]
PD-0325901 + MK-1775 DC52AAC PD-0325901 Adenocarcinoma (Cell Line: CAOV3) [4]
PD-0325901 + MK-1775 DCBKUKX PD-0325901 Adenocarcinoma (Cell Line: A427) [4]
PD-0325901 + MK-1775 DC28KYC PD-0325901 Adenocarcinoma (Cell Line: NCIH2122) [4]
PD-0325901 + MK-1775 DCO2K32 PD-0325901 Adenocarcinoma (Cell Line: NCIH23) [4]
PD-0325901 + MK-1775 DCT7X54 PD-0325901 Adenocarcinoma (Cell Line: NCIH520) [4]
PD-0325901 + MK-1775 DCWY96T PD-0325901 Adenocarcinoma (Cell Line: COLO320DM) [4]
PD-0325901 + MK-1775 DCDCKX0 PD-0325901 Adenocarcinoma (Cell Line: HCT116) [4]
PD-0325901 + MK-1775 DC7WLDW PD-0325901 Adenocarcinoma (Cell Line: HT29) [4]
PD-0325901 + MK-1775 DCL4ZJK PD-0325901 Adenocarcinoma (Cell Line: SW-620) [4]
PD-0325901 + MK-1775 DCETMOX PD-0325901 Amelanotic melanoma (Cell Line: A2058) [4]
PD-0325901 + MK-1775 DCYA9O9 PD-0325901 Embryonal rhabdomyosarcoma (Cell Line: Rh36) [4]
PD-0325901 + MK-1775 DCVBZ23 PD-0325901 Germ cell tumour (Cell Line: PA1) [4]
PD-0325901 + MK-1775 DCS9I1Z PD-0325901 Hodgkin lymphoma (Cell Line: U-HO1) [4]
PD-0325901 + MK-1775 DC65KUW PD-0325901 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
PD-0325901 + MK-1775 DCJJM4H PD-0325901 Malignant melanoma (Cell Line: A375) [4]
PD-0325901 + MK-1775 DCRE1RK PD-0325901 Malignant melanoma (Cell Line: HT144) [4]
PD-0325901 + MK-1775 DCFHXFG PD-0325901 Malignant melanoma (Cell Line: RPMI7951) [4]
PD-0325901 + MK-1775 DC7Z7WH PD-0325901 Malignant melanoma (Cell Line: SKMEL30) [4]
PD-0325901 + MK-1775 DC17Y5D PD-0325901 Malignant melanoma (Cell Line: UACC62) [4]
PD-0325901 + MK-1775 DCHZLFO PD-0325901 Non small cell carcinoma (Cell Line: SKMES1) [4]
PD-0325901 + MK-1775 DCNY7EA PD-0325901 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
PD-0325901 + MK-1775 DC9PZHI PD-0325901 Prostate carcinoma (Cell Line: LNCAP) [4]
PD-0325901 + MK-1775 DCXVYDI PD-0325901 Prostate carcinoma (Cell Line: VCAP) [4]
PMID28460551-Compound-2 + MK-1775 DC2LNBX PMID28460551-Compound-2 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
PMID28460551-Compound-2 + MK-1775 DCBF5N7 PMID28460551-Compound-2 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [5]
PMID28460551-Compound-2 + MK-1775 DCO4O3W PMID28460551-Compound-2 Breast carcinoma (Cell Line: ZR751) [5]
PMID28460551-Compound-2 + MK-1775 DCWDHM4 PMID28460551-Compound-2 Carcinoma (Cell Line: EFM192B) [5]
PMID28460551-Compound-2 + MK-1775 DCD19FK PMID28460551-Compound-2 Invasive ductal carcinoma (Cell Line: T-47D) [5]
PMID28460551-Compound-2 + MK-1775 DCPO0RH PMID28460551-Compound-2 Rectal adenocarcinoma (Cell Line: SW837) [5]
PMID28460551-Compound-2 + MK-1775 DCJCM39 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH2122) [4]
PMID28460551-Compound-2 + MK-1775 DCCXX9J PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH520) [4]
PMID28460551-Compound-2 + MK-1775 DCUOYG5 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: COLO320DM) [4]
PMID28460551-Compound-2 + MK-1775 DCYFW4R PMID28460551-Compound-2 Adenocarcinoma (Cell Line: DLD1) [4]
PMID28460551-Compound-2 + MK-1775 DCYUU2H PMID28460551-Compound-2 Adenocarcinoma (Cell Line: HCT116) [4]
PMID28460551-Compound-2 + MK-1775 DCH8KAJ PMID28460551-Compound-2 Adenocarcinoma (Cell Line: HT29) [4]
PMID28460551-Compound-2 + MK-1775 DCVOJXD PMID28460551-Compound-2 Adenocarcinoma (Cell Line: SW-620) [4]
PMID28460551-Compound-2 + MK-1775 DCUTYLL PMID28460551-Compound-2 Amelanotic melanoma (Cell Line: A2058) [4]
PMID28460551-Compound-2 + MK-1775 DCEET63 PMID28460551-Compound-2 Germ cell tumour (Cell Line: PA1) [4]
PMID28460551-Compound-2 + MK-1775 DC3ZEIN PMID28460551-Compound-2 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
PMID28460551-Compound-2 + MK-1775 DCT2GR0 PMID28460551-Compound-2 Malignant melanoma (Cell Line: A375) [4]
PMID28460551-Compound-2 + MK-1775 DCE14RQ PMID28460551-Compound-2 Malignant melanoma (Cell Line: RPMI7951) [4]
PMID28460551-Compound-2 + MK-1775 DCPAH12 PMID28460551-Compound-2 Mesothelioma (Cell Line: MSTO) [4]
PMID28460551-Compound-2 + MK-1775 DCZCR8K PMID28460551-Compound-2 Non small cell carcinoma (Cell Line: SKMES1) [4]
PMID28460551-Compound-2 + MK-1775 DCCKWO2 PMID28460551-Compound-2 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
PMID28460551-Compound-2 + MK-1775 DC7UTW2 PMID28460551-Compound-2 Prostate carcinoma (Cell Line: LNCAP) [4]
PMID28460551-Compound-2 + MK-1775 DCYXUY0 PMID28460551-Compound-2 Prostate carcinoma (Cell Line: VCAP) [4]
Pyrazinamide + MK-1775 DCAV3PJ Pyrazinamide Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
SCH 727965 + MK-1775 DCG2B84 SCH 727965 Breast carcinoma (Cell Line: OCUBM) [5]
SCH 727965 + MK-1775 DC7BFLH SCH 727965 Colon adenocarcinoma (Cell Line: LOVO) [5]
SCH 727965 + MK-1775 DCZ6Z2X SCH 727965 Invasive ductal carcinoma (Cell Line: T-47D) [5]
SCH 727965 + MK-1775 DCTHQ0O SCH 727965 Adenocarcinoma (Cell Line: CAOV3) [4]
SCH 727965 + MK-1775 DCRTG0L SCH 727965 Adenocarcinoma (Cell Line: OVCAR3) [4]
SCH 727965 + MK-1775 DCKN2J6 SCH 727965 Adenocarcinoma (Cell Line: NCIH2122) [4]
SCH 727965 + MK-1775 DCV83HO SCH 727965 Adenocarcinoma (Cell Line: NCIH520) [4]
SCH 727965 + MK-1775 DCAOUYE SCH 727965 Adenocarcinoma (Cell Line: COLO320DM) [4]
SCH 727965 + MK-1775 DCP2EGW SCH 727965 Adenocarcinoma (Cell Line: DLD1) [4]
SCH 727965 + MK-1775 DCKSW32 SCH 727965 Adenocarcinoma (Cell Line: HT29) [4]
SCH 727965 + MK-1775 DCELXAQ SCH 727965 Amelanotic melanoma (Cell Line: A2058) [4]
SCH 727965 + MK-1775 DCELEVY SCH 727965 Malignant melanoma (Cell Line: A375) [4]
SCH 727965 + MK-1775 DC9AJ7L SCH 727965 Malignant melanoma (Cell Line: HT144) [4]
SCH 727965 + MK-1775 DCQVUW2 SCH 727965 Malignant melanoma (Cell Line: RPMI7951) [4]
SCH 727965 + MK-1775 DC5EHSD SCH 727965 Malignant melanoma (Cell Line: SKMEL30) [4]
SCH 727965 + MK-1775 DCN32GL SCH 727965 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
SCH 727965 + MK-1775 DC6QENA SCH 727965 Prostate carcinoma (Cell Line: VCAP) [4]
SCH-900776 + MK-1775 DCDWQ24 SCH-900776 Ewing sarcoma (Cell Line: TC-71) [3]
SNX-5422 + MK-1775 DCKIH13 SNX-5422 Ewing sarcoma (Cell Line: TC-71) [3]
Taxol + MK-1775 DCOZ0EB Taxol Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Taxol + MK-1775 DC6H2ID Taxol Adenocarcinoma (Cell Line: COLO320DM) [4]
Taxol + MK-1775 DC3K8EN Taxol Germ cell tumour (Cell Line: PA1) [4]
Taxol + MK-1775 DCGYJZA Taxol Malignant melanoma (Cell Line: RPMI7951) [4]
Taxol + MK-1775 DCD58VV Taxol Malignant melanoma (Cell Line: A375) [4]
Taxol + MK-1775 DCKR90C Taxol Mesothelioma (Cell Line: MSTO) [4]
Taxol + MK-1775 DCWQJ5C Taxol Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Teriflunomide + MK-1775 DCCJH6Y Teriflunomide Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
Tivantinib + MK-1775 DCDSN9I Tivantinib Ewing sarcoma (Cell Line: TC-71) [4]
Topotecan + MK-1775 DCGY7GB Topotecan Adenocarcinoma (Cell Line: NCIH2122) [4]
Topotecan + MK-1775 DC7QUPF Topotecan Adenocarcinoma (Cell Line: COLO320DM) [4]
Topotecan + MK-1775 DCJ8H74 Topotecan Adenocarcinoma (Cell Line: DLD1) [4]
Topotecan + MK-1775 DCC5MCG Topotecan Adenocarcinoma (Cell Line: HCT116) [4]
Topotecan + MK-1775 DCJZG2O Topotecan Adenocarcinoma (Cell Line: HT29) [4]
Topotecan + MK-1775 DCU46KT Topotecan Adenocarcinoma (Cell Line: SW-620) [4]
Topotecan + MK-1775 DCU12WP Topotecan Amelanotic melanoma (Cell Line: A2058) [4]
Topotecan + MK-1775 DC1LCTT Topotecan Germ cell tumour (Cell Line: PA1) [4]
Topotecan + MK-1775 DC3H1AG Topotecan Malignant melanoma (Cell Line: A375) [4]
Topotecan + MK-1775 DCMXLK1 Topotecan Malignant melanoma (Cell Line: SKMEL30) [4]
Topotecan + MK-1775 DCP5151 Topotecan Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Topotecan + MK-1775 DC4R94Q Topotecan Prostate carcinoma (Cell Line: VCAP) [4]
Tosyl-l-arginine methyl ester + MK-1775 DCH6IVL Tosyl-l-arginine methyl ester Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
Venglustat + MK-1775 DCA9Q2J Venglustat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
Verteporfin + MK-1775 DCLS3C5 Verteporfin Ewing sarcoma (Cell Line: TC-71) [3]
Vinblastine + MK-1775 DCEHULI Vinblastine Adenocarcinoma (Cell Line: NCIH2122) [3]
Vinblastine + MK-1775 DC08B58 Vinblastine Adenocarcinoma (Cell Line: COLO320DM) [3]
Vinblastine + MK-1775 DCGGZ6O Vinblastine Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Vinblastine + MK-1775 DCYUD0X Vinblastine Malignant melanoma (Cell Line: RPMI7951) [3]
Vinblastine + MK-1775 DC5IP4V Vinblastine Malignant melanoma (Cell Line: SKMEL30) [3]
Vinblastine + MK-1775 DCHR8L8 Vinblastine Malignant melanoma (Cell Line: UACC62) [3]
Vinblastine + MK-1775 DCICDHX Vinblastine Mesothelioma (Cell Line: MSTO) [3]
Vinblastine + MK-1775 DCSUA27 Vinblastine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Vinblastine + MK-1775 DCVRA3E Vinblastine Prostate carcinoma (Cell Line: VCAP) [3]
Vinblastine + MK-1775 DCIAUA6 Vinblastine Breast carcinoma (Cell Line: OCUBM) [5]
Vinblastine + MK-1775 DCMG4XG Vinblastine Colon carcinoma (Cell Line: RKO) [5]
Vinorelbine + MK-1775 DC32991 Vinorelbine Breast carcinoma (Cell Line: OCUBM) [5]
Vinorelbine + MK-1775 DCBLUPJ Vinorelbine Invasive ductal carcinoma (Cell Line: T-47D) [5]
Vinorelbine + MK-1775 DC2SARV Vinorelbine Adenocarcinoma (Cell Line: NCIH2122) [4]
Vinorelbine + MK-1775 DCBZZK5 Vinorelbine Adenocarcinoma (Cell Line: COLO320DM) [4]
Vinorelbine + MK-1775 DCVZ16M Vinorelbine Adenocarcinoma (Cell Line: HCT116) [4]
Vinorelbine + MK-1775 DC9W253 Vinorelbine Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vinorelbine + MK-1775 DC12MU8 Vinorelbine Malignant melanoma (Cell Line: SKMEL30) [4]
Vinorelbine + MK-1775 DCHLNHA Vinorelbine Non small cell carcinoma (Cell Line: SKMES1) [4]
Vinorelbine + MK-1775 DCAFR89 Vinorelbine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Zoledronate + MK-1775 DCG1XF8 Zoledronate Ewing sarcoma (Cell Line: TC-71) [3]
Zoledronate + MK-1775 DCWZBEB Zoledronate Embryonal rhabdomyosarcoma (Cell Line: Rh36) [4]
Zoledronate + MK-1775 DCSL34J Zoledronate Hodgkin lymphoma (Cell Line: U-HO1) [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 676 DrugCom(s)
11 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
MK-1775 + Gemcitabine DCENERW Gemcitabine Solid Tumors [6]
MK-1775 + Itraconazole DC0DPZ7 Itraconazole Advanced Solid Tumours [7]
MK-1775 + Olaparib DCBRNND Olaparib Advanced Malignant Solid Neoplasm [8]
MK-1775 + Carboplatin DCCRI37 Carboplatin Pediatric Cancer [9]
MK-1775 + Omeprazole DCCT636 Omeprazole Advanced Solid Tumours [7]
MK-1775 + Rifampicin DCO7VD4 Rifampicin Advanced Solid Tumours [7]
MK-1775 + Belinostat DCY1LOX Belinostat Acute Myeloid Leukemia [10]
MK-1775 + Docetaxel DCD4BKP Docetaxel Lung Cancer [11]
MK-1775 + Olaparib DC3YX8K Olaparib Recurrent Fallopian Tube Carcinoma [12]
MK-1775 + Paclitaxel DCKW17N Paclitaxel Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation [13]
MK-1775 + Carboplatin DCUBPZK Carboplatin Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation [13]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 DrugCom(s)

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7702).
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
5 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
6 ClinicalTrials.gov (NCT00648648) A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)
7 ClinicalTrials.gov (NCT04959266) A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib
8 ClinicalTrials.gov (NCT04197713) Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study
9 ClinicalTrials.gov (NCT02813135) European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
10 ClinicalTrials.gov (NCT02381548) Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
11 ClinicalTrials.gov (NCT02513563) AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
12 ClinicalTrials.gov (NCT03579316) Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
13 ClinicalTrials.gov (NCT02272790) Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer